167 related articles for article (PubMed ID: 24204699)
1. Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer.
Koskensalo S; Louhimo J; Hagström J; Lundin M; Stenman UH; Haglund C
PLoS One; 2013; 8(10):e76906. PubMed ID: 24204699
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
[TBL] [Abstract][Full Text] [Related]
3. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
4. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
6. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.
Gaber A; Johansson M; Stenman UH; Hotakainen K; Pontén F; Glimelius B; Bjartell A; Jirström K; Birgisson H
Br J Cancer; 2009 May; 100(10):1540-8. PubMed ID: 19384300
[TBL] [Abstract][Full Text] [Related]
7. TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer.
Björkman K; Kaprio T; Beilmann-Lehtonen I; Stenman UH; Böckelman C; Haglund C
Oncology; 2022; 100(1):22-30. PubMed ID: 34794144
[TBL] [Abstract][Full Text] [Related]
8. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
[TBL] [Abstract][Full Text] [Related]
9. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C
Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949
[TBL] [Abstract][Full Text] [Related]
10. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
Rink M; Park K; Volkmer BG; Xylinas E; Hansen J; Cha EK; Robinson BD; Hautmann R; Küfer R; Engel O; Chun FK; Dahlem R; Rubin MA; Shariat SF; Mosquera JM
Urol Oncol; 2013 Nov; 31(8):1716-24. PubMed ID: 22944196
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas.
Solakidi S; Tiniakos DG; Petraki K; Stathopoulos GP; Markaki I; Androulakis G; Sekeris CE
Histol Histopathol; 2003 Oct; 18(4):1181-8. PubMed ID: 12973686
[TBL] [Abstract][Full Text] [Related]
12. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
Lippolis G; Edsjö A; Stenman UH; Bjartell A
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
[TBL] [Abstract][Full Text] [Related]
13. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
Beyene DA; Naab TJ; Kanarek NF; Apprey V; Esnakula A; Khan FA; Blackman MR; Brown CA; Hudson TS
Prostate; 2018 Aug; 78(11):801-811. PubMed ID: 29682763
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
16. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.
Gaber A; Stene C; Hotakainen K; Nodin B; Palmquist I; Bjartell A; Stenman UH; Jeppsson B; Johnson LB; Jirström K
Radiat Oncol; 2011 Aug; 6():100. PubMed ID: 21864386
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
Hotakainen K; Bjartell A; Sankila A; Järvinen R; Paju A; Rintala E; Haglund C; Stenman UH
Int J Oncol; 2006 Jan; 28(1):95-101. PubMed ID: 16327984
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma.
Lyytinen I; Lempinen M; Nordin A; Mäkisalo H; Stenman UH; Isoniemi H
Scand J Gastroenterol; 2013 Sep; 48(9):1066-73. PubMed ID: 23889187
[TBL] [Abstract][Full Text] [Related]
19. Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer.
Larsson AH; Lehn S; Wangefjord S; Karnevi E; Kuteeva E; Sundström M; Nodin B; Uhlén M; Eberhard J; Birgisson H; Jirström K
J Transl Med; 2016 May; 14(1):128. PubMed ID: 27160084
[TBL] [Abstract][Full Text] [Related]
20. Emerging Roles of SPINK1 in Cancer.
Räsänen K; Itkonen O; Koistinen H; Stenman UH
Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]